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Background: Laryngo-pharyngeal reflux (LPR) is assumed to be the most common cause of posterior laryngitis (PL).
Since LPR is found in healthy subjects, and PL patients are not improved by acid-reducing therapy, other
aetiologies to PL must be considered. The aims of this study in PL were to investigate the prevalence of acid reflux
in the proximal oesophagus and functional gastrointestinal symptoms, to analyse motilin levels in plasma, and to
assess health-related quality of life (HRQOL) before and after treatment.
Methods: Forty-six patients (26 women), with verified PL, median age 55 (IQR 41–68) years, were referred to
oesophago-gastro-duodenoscopy and 24-h pH monitoring. Plasma motilin was analysed. The 36-item Short-Form
questionnaire was completed at inclusion and at follow-up after 43±14 months, when also the Visual Analogue
Scale for Irritable Bowel Syndrome was completed. Values were compared to controls. Treatment and relief of
symptoms were noted from medical records.
Results: Thirty-four percent had proximal acid reflux and 40% showed signs of distal reflux. Ninety-four percent received
acid-reducing treatment, with total relief of symptoms in 17%. Patients with reflux symptoms had lower plasma motilin
levels compared to patients without reflux symptoms (p = 0.021). The HRQOL was impaired at inclusion, but improved
over time. Patients, especially men, had more functional gastrointestinal symptoms than controls.
Conclusions: This study indicates that a minority of patients with PL has LPR and is cured by acid-reducing therapy.
Disturbed plasma motilin levels and presence of functional gastrointestinal symptoms are found in PL. The impaired
HRQOL improves over time.
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Health-related quality of lifeBackground
Posterior laryngitis (PL) is defined as an inflammation
involving the most posterior part of the glottic region,
and sometimes involving the oesophageal inlet, in
conjunction with symptoms such as chronic cough,
hoarseness, a sensation of having a lump in the throat
(globus), excessive throat clearing, excessive phlegm,
voice fatigue, throat pain and dysphagia [1-4]. The* Correspondence: Hillevi.Pendleton@med.lu.se
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distribution, and reproduction in any mediumpathogenesis of inflammation is multifactorial and
smoking, alcohol abuse, viral or bacterial infections,
allergy, chronic sinusitis, voice abuse, and laryngo-
pharyngeal reflux (LPR) can be the underlying causes.
LPR is defined as a back flow of gastric contents
into the laryngo-pharynx and can be established by
objective measurements [5]. A previous study indicate
that 4%−10% of the patients who visit a Department
of Oto-Rhino-Laryngology have complaints related to
LPR [2]. One study showed that as many as 50% of
patients affected by laryngeal and voice disorders have a
pH-documented reflux [1]. Although the exact mechan-
ism is unknown, reflux is associated with oesophagealtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the lower oesophageal sphincter (LOS) in the majority of
cases [6-8]. The influences on the function of the LOS are
numerous. Motilin is an intestinal hormone, which
regulates the migrating motor complex (MMC) of the
ventricle and affects the pressure of the LOS. The
hormone is found in enterochromaffin cells in the
duodenum and jejunum, and ingestion of fat and gastric
acid stimulates secretion of motilin into the bloodstream
[9,10]. Patients with reflux have been shown to have
altered motilin levels [11].
Patients with PL are at risk of being over-diagnosed as
having extra-oesophageal acid reflux, as LPR is the most
often assumed aetiology of PL [12,13]. Consequently, an
inappropriate use of proton pump inhibitors (PPIs) are
prescribed even though the symptoms and the findings
are not related to acid reflux [14]. It has recently been
shown that patients with PL, despite treatment with
sufficient doses of PPI over many years, still suffer from
their initial symptoms and complaints, with impaired
health-related quality of life (HRQOL) as a result [15].
Apart from acid reflux, functional heartburn, functional
dyspepsia and functional oesophageal disease may lead to
oesophageal complaints [16]. An overlap and comorbidity
between different functional disorders often exists.
This also applies to functional gastrointestinal disorders
(FGID), one of the most common being irritable bowel
syndrome (IBS) [17]. The reason to functional disturbances
is unclear, but may depend on altered central processing of
visceral afferent information [18], where patients with FGID
are thought to have a heightened perception of normal
visceral stimuli, called visceral hypersensitivity [19-21].
The same functional aetiology has also been suggested
in the case of PL [13,15].
Aim
The primary aim of the present study of PL was to
investigate how many of the patients who had acid reflux
in the proximal part of the oesophagus. Secondary aims
were to examine motilin levels in plasma; to determine
whether PL was associated with symptoms of FGID; and
to register the HRQOL before and after treatment.
Methods
This study was performed according to the Helsinki
declaration, and was approved by the Regional Ethics
Review Board at Lund University. Informed, written
consent was obtained from the participants.
Subjects
All consecutive patients, >18 years of age, from the
Department of Oto-Rhino-Laryngology, Skåne University
Hospital, Malmö, were invited during the period June
2007 to May 2011 to participate in the study when thediagnosis PL was made by fibre optic laryngoscopy of an
examiner not blinded to the patients symptoms. The diag-
nosis criteria for PL [1-4], and thereby the criteria for
inclusion in the study, were the thickening and/or oedema
of the posterior part of the glottic region in combination
with one or several of the following symptoms: chronic
cough, hoarseness, a sensation of having a lump in
the throat (globus), excessive throat clearing, excessive
phlegm, voice fatigue, throat pain and dysphagia. Patients
with signs of PL but no symptoms were not enrolled in
the study. Additional exclusion criteria were inflammatory
bowel disease (IBD), coeliac disease, pregnancy, serious
illness such as severe heart, lung, liver or kidney diseases
and mental illness. Patients with Hepatitis B, C and
HIV/AIDS were not included.
Study design
At the time of inclusion, age, symptoms and findings
typical of the diagnosis PL, duration of symptoms, previous
treatment for acid-related disease and symptoms, and
tobacco and alcohol habits were registered. The patients
were asked to fill in the 36-item Short-Form questionnaire
(SF-36) to evaluate HRQOL. All patients were referred to a
single-probe, 24-h pH monitoring in the proximal part of
the oesophagus and an oesophago-gastro-duodenoscopy
(OGD). An instant test for Helicobacter Pylori was made at
OGD when clinically indicated. Blood samples were
collected for the analysis of motilin.
At follow-up 43 ± 14 months later, a letter including
the questionnaire SF-36 and the Visual Analogue Scale
for Irritable Bowel Syndrome (VAS-IBS) was sent to
the patients. Medical records were scrutinized and
information such as choice of treatment (kind of drug,
dosage and duration of treatment) and the extent of relief
of symptoms were noted.
Ambulatory 24-h pH monitoring
All participants were instructed to cease their PPI therapy
seven days before, and other acid inhibitors 16 h before
the monitoring. They were asked to avoid acid beverages,
e.g. fruit juice, during the 24-h duration of the pH moni-
toring and to fast 4 h before the catheter was introduced.
The positioning of the catheter was performed in the
Diagnostic Centre of Imaging and Functional Medicine,
with the aid of fluoroscopy (Philips Multidiagnost Eleva,
CA, USA). The catheter was introduced through the nose
and under fluoroscopic control positioned in the proximal
part of the oesophagus, 5 cm below the upper oesophageal
sphincter.
Ambulatory pH monitoring for proximal reflux was
performed for 24 h. Oesophageal pH monitoring was
performed using an antimony pH electrode with an
internal reference electrode (Versaflex, Sierra Scientific
Instruments, Los Angeles, Ca, USA). Before each study,
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and 1. An episode of acid reflux was defined as a decrease
in oesophageal pH to below 4 for more than 10 s. Previously
established upper limits of normal acid exposure in clinical
studies, with pH < 4 for 1% of total time, were used in the
analysis of the data [22,23]. The data were stored on
a portable digital recorder (Digitrapper pH400, Synectics
Medical, Stockholm, Sweden) and were analysed with
commercially available software (Polygram NET, SynMed
Medical, Stockholm, Sweden).
Measurements of motilin
After fasting for at least 9 h, blood samples were taken
at the time of the OGD. All blood samples consisted of
8.0 ml whole blood drawn into heparinised tubes. The
plasma was separated and frozen at −20°C within 1 h of
collection. Plasma motilin was measured as previously
described by a radioimmunoassay (RIA) using a rabbit
antiserum (R-8423), raised against highly purified, porcine
motilin. The antiserum is directed to the NH2-terminal of
motilin (amino acids 1–9). The coefficient of variation,
intra-assay CV, was < 8% for controls at 140 pmol/l [24].
Questionnaires
The 36-item short-form questionnaire
SF-36 is an extensively used HRQOL instrument, which
provides reproducible, reliable data on large populations,
and has been shown to be useful as a global health
monitor in clinical practice [25]. It is available in
Swedish [26], and Swedish reference data are available
for many different conditions. The SF-36 questionnaire is
divided into eight subscales of general health, arranged
according to the degree to which they measure physical
vs. mental health. These subscales are physical functioning
(PF), role functioning-physical (RP), bodily pain (BP),
general health (GH), vitality (VT), social functioning
(SF), role functioning-emotional (RE), and mental health
(MH). Two additional dimensions can be calculated,
physical (PCS) and emotional health (MCS), based on
the weighting of the importance of the other eight
subscales. The raw data were recoded at the time of
analysis; the maximum score is 100, the higher score
the better the HRQOL.
The visual analogue scale for irritable bowel disease
The VAS-IBS questionnaire is designed to measure
the symptoms, the response to the treatment, and
well-being in patients suffering from IBS. It was previously
developed and validated for patients with gastrointestinal
symptoms without organic causes [27]. Patients estimated
seven different aspects of their gastrointestinal condition
on a visual analogue scale (VAS) from 0–100 mm, where
0 represents very severe problems and 100 represents
absence of problems. The aspects are abdominal pain,diarrhoea, constipation, bloating and flatulence, vomiting
and nausea, perception of psychological well-being
and the intestinal symptoms' influence on daily life. It
also contains two additional questions concerning the
patient's sense of urgency to defecate and the feeling
of incomplete evacuation after defecation, which can
be answered by “yes” or “no”.
Statistical analyses
The data were analysed using the statistical software
package SPSS for Windows© (Release 20.0; IBM).
Distribution among the study population was tested
by the Kolmogorov-Smirnov test and differed significantly
from a normal distribution (p < 0.001) regarding age,
VAS-IBS, and motilin levels. Results are given as means
and the standard error of the mean (SEM) or median and
interquartile range (IQR). Differences between groups
were calculated, when appropriate by the Mann–Whitney
U-test. Fisher’s exact test was used for categorical variables
and Spearman rank correlation test was used for correla-
tions. The one-sample t-test was used to compare data
from the SF-36 questionnaire with the Swedish reference
values. Values were compared with the norm values of the
general, and the Swedish female and male population,
corrected for age [26]. As the patient group was older than
the controls for VAS-IBS, the VAS variables were age-
standardized using a linear regression model into which age
was added as a covariate (independent). The dependent
variables abdominal pain, diarrhoea, constipation, bloating
and flatulence, vomiting, nausea, perception of psycho-
logical well-being, and the intestinal symptoms' influence
on daily life were expressed as z-scores. As symptoms differ
between gender [28], the results for women and men were
calculated separately. Logistic regression analysis, adjusted
for age (divided into 5-year intervals) and gender, was used
to calculate odds ratios with 95% confidence intervals
(OR with 95% CI) for the prevalence of the patient's
sense of urgency to defecate and whether the bowel
was totally emptied after defecation. The level of statistical




Forty-six out of 60 invited patients with verified PL
(26 women), median age 55 (IQR 41–68) years, accepted
to participate and were included in the study. Fourteen
patients did not want to participate, the majority declining
without giving a reason. Thirty-five patients tolerated the
24-h pH monitoring, 37 patients agreed to give blood
samples for analysis of motilin, 42 patients were examined
by OGD, and 44 patients filled in the SF-36 questionnaire
(Figure 1). The mean duration of the disease was 13.5


















Figure 1 Flow-chart illustrating the selection process and the
number of procedures among the included patients.
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hoarseness (37%), voice fatigue (26%), and heartburn
(26%) (Table 1). At fibre laryngoscopy, signs of PL such as
inter-arytenoid pachydermia (76%), arytenoid oedema
(56%), post-cricoid oedema (22%), and erythema of the
vocal folds (11%) were found. Seventeen (11%) of the
patients were smokers and 14 (9%) had been treated
for dyspepsia, gastro-oesophageal reflux disease (GORD)
or ulcer before their visit to the ear, nose and throat
specialist. Five patients had a previously found hiatal
hernia. Information about drinking habits was lacking
in the majority of the cases.
Ambulatory 24-h pH monitoring and OGD
Thirty-four percent, 12 of the 35 patients examined
(6 women), median age 55 (IQR 30–70) years, had a
pathological reflux to the proximal oesophagus. Voice
problems were associated with a pathological 24-h pH
monitoring result (p = 0.050).
No ulcerations or tumours were found at OGD, but
seven suffered from oesophagitis, 10 from Barrett'sTable 1 The prevalence of the various symptoms in the
patients with posterior laryngitis (n=46)
Symptomsa Number and percentage of patients
Globus 28 (61)
Excessive phlegm 22 (48)
Hoarseness 17 (37)
Heartburn 12 (26)
Voice fatigue 12 (26)
Acid regurgitation/reflux 11 (24)
Coughing 11 (24)
Excessive throat clearing 11 (24)
Dysphagia 9 (20)
Breathing difficulties 1 (2)
aMore than one symptom for each patient was registered.oesophagus, 14 from hiatal hernia and 14 had normal
OGDs. Of the 12 patients complaining of voice problems,
11 were examined by OGD. The results of this procedure
showed that these patients suffered from one or several
of the following findings: five patients had a hiatal
hernia, three suffered from Barrett’s metaplasia, two
had oesophagitis and one patient was positive for
Helicobacter Pylori. Two patients had normal OGDs.
Measurements of motilin
Thirty-seven patients (20 women), median age 55
(IQR 40–67) years, gave blood samples for the analysis of
motilin. Twenty-one healthy volunteers (14 women),
median age 43 (IQR 36–53) years, served as controls. The
motilin levels showed no correlations with age (rs = 0.180,
p = 0.287). There were no differences in plasma levels of
motilin between patients and controls (p = 0.517), but the
motilin levels differed between patients reporting typical
reflux symptoms, i.e. heartburn and/or regurgitations
(median 61 (IQR 52–68) pmol/l), compared to those
without reflux symptoms (median 71 (IQR 64–85) pmol/l)
(p = 0.021). There were no differences in plasma levels of
motilin between patients with a positive or negative 24-h
pH monitoring result (p = 0.057) or between patients with
a pathological or normal OGD (p = 0.441).
SF-36
The women had significantly lower scores for all sub-
scales, except PF that did not differ from the Swedish
female population (p = 0.264) or the general Swedish
population (p = 0.116) (Figure 2). In men, no differences
in scores were found compared to the general Swedish
population (Figure 2). The score for MH was significantly
lower in the PL group compared to the Swedish male
population (p = 0.050). The total PL population (n = 44)Figure 2 Analysis of the SF-36 questionnaire at inclusion in the
population of men and women with posterior laryngitis (PL)
and the general Swedish population. Gender- and age-matched
values are presented as mean values. PF = physical functioning,
RP = role-physical, BP = bodily pain, GH = general health, VT = vitality,
SF = social functioning, RE = role-emotional, ME = mental health.
One-sample t-test. P ≤ 0.050 was considered statistically significant.
Figure 3 Analysis of the SF-36 questionnaire at follow-up in the
population of men and women with posterior laryngitis (PL)
and the general Swedish population. Gender- and age-matched
values are presented as mean values. PF = physical functioning,
RP = role-physical, BP = bodily pain, GH = general health, VT = vitality,
SF = social functioning, RE = role-emotional, ME = mental health.
One-sample t-test. P ≤ 0.050 was considered statistically significant.
Pendleton et al. BMC Ear, Nose and Throat Disorders 2013, 13:11 Page 5 of 8
http://www.biomedcentral.com/1472-6815/13/11had significantly lower scores for all subscales except PF
and RP, compared to the general Swedish population
(data not shown).
Treatment results
Forty-three patients (94%) received acid-reducing treat-
ment. The most common treatment prescribed was PPIs
alone or in combination with alginic acid (Table 2). The
preferred choice of dose and duration of treatment was
20 mg PPI twice daily for 2–3 months. About one-fifth
of the patients were treated for 8 weeks or less and 16%
were treated for 4 weeks or less. At the clinical follow-up,
more than half of the patients were better, but only 17%
were asymptomatic (Table 2). An appointment with the
physician, with a renewed fibre optic examination of the
larynx was the most common mode of follow-up (52%),
whereas 44% of the patients were followed by a telephone
consultation. Two patients had no follow-up.
Follow-up
At study follow-up, 40 patients (22 women), median
age 61 (IQR 44–72) years, completed both SF-36 and
VAS-IBS.
SF-36
The women had a significantly lower score for the
subscale GH compared to the general Swedish popula-
tion (p = 0.046) (Figure 3), but no significant difference
was noted compared to the Swedish female population
(data not shown). In men, no differences in scores
were found compared to the general Swedish popula-
tion (Figure 3) or to the Swedish male population
(data not shown). The total PL population had signifi-
cantly lower scores in the subscales RP (p = 0.047),
GH (p = 0.016), and VT (p = 0.028) compared to the
general Swedish population.Table 2 Medical treatment and results of treatment (n = 46)
Patients n (%)
Medical treatmenta
Proton pump inhibitor 41 (89)
Alginic acid 13 (28)
Histamine receptor blocker 2 (4)
Aluminum dihydroxide 0 (0)
Missing information 3 (7)
Relief of symptoms
Complete lack of symptoms 8 (17)
Improved 26 (57)
No change 9 (20)
Worse 1 (2)
Missing information 2 (4)
aSome patients were treated with more than one drug.Visual analogue scale for irritable bowel syndrome
Eighty-three volunteers (65 women), median age 39
(IQR 35–44) years, not suffering from PL or severe
organic disease, served as controls for the VAS-IBS
questionnaire. Women in the PL group registered sig-
nificantly lower scores than the controls concerning
abdominal pain (AP) (p = 0.001). The men in the PL
group rated their symptoms as more severe than the con-
trols, with a significant difference concerning abdom-
inal pain (AP) (p<0.001), bloating and flatulence (BF)
(p = 0.042), perception of psychological well-being
(PW) (p = 0.024), and their intestinal symptoms' influence
on daily life (IDL) (p = 0.020) (Figure 4). A positive correl-
ation was found between emotional health (MCS) and
perception of psychological well-being (WB) (rs = 0.542,
p = 0.001) and intestinal symptoms' influence on daily
life (IDL) (rs = 0.423, p = 0.009). There was no correlation
between physical health (PCS) and the VAS-IBS
(data not shown).
There was no significant difference between the PL
group and the controls concerning the patient's sense of
urgency to defecate (OR = 1.497, 95% CI = 0.233−9.605,
p = 0.670) or the feeling of incomplete evacuation
after defecation (OR = 1.494, 95% CI = 0.340−6.569,
p = 0.595).
Discussion
The majority of the patients with PL in the present study
had been prescribed acid-reducing treatment. However,
only a minority of the patients were asymptomatic at
clinical follow-up. Although the patients were perceived
as having LPR-induced inflammation, only 34% of the
patients with typical signs and symptoms of PL had a
proximal acid reflux and associated voice problems. At
Figure 4 Analysis of the VAS-IBS questionnaire, expressed as
median z-scores, for the PL group and the controls at follow-up.
AP = abdominal pain, D = diarrhoea, C = constipation, BF = bloating
and flatulence, VN = vomiting and nausea, PW = perception
of mental well-being, IDL = intestinal symptoms effect on daily
life. Mann–Whitney U-test. P ≤ 0.050 was considered statistically
significant. * = Significant difference to controls-women,
** = Significant difference to controls-men.
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There was no difference in plasma levels of motilin
between patients and controls, but patients with reflux
symptoms had lower motilin levels compared to those
without these symptoms. The total PL population's
HRQOL was improved during the study, and the
women's HRQOL improved more than the men’s. The
PL group, especially the men, experienced functional
symptoms from the gastrointestinal tract to a greater
extent than controls.
The terminology concerning PL and LPR is unclear
and the terms are used synonymously. Patients included
in studies are defined to have LPR when they actually
have signs and symptoms of PL and vice versa [29,30].
Laryngo-pharyngeal reflux has been observed in healthy
subjects without any association to typical symptoms of
PL [31-34]. Further, Ylitalo et al. [35] could not prove a
significant difference in the occurrence of any specific
pharyngeal or laryngeal symptom or finding between the
patients with and without extra-oesophageal reflux in
patients with chronic heartburn. Although LPR has been
shown to be more prevalent in PL patients than in con-
trols, LPR does not render specific laryngeal symptoms
[32]. This indicates an incomplete concordance between
symptoms, objective findings and reflux in PL, and that
the diagnosis cannot be based on symptoms alone
[5,32]. Nevertheless, it is assumed that most patients
suffering from PL have reflux of gastric content into
the pharynx and larynx, LPR.
In the current study, all patients included displayed
typical findings and symptoms of PL, but only 34% ofthe patients had a pathological 24-h pH value. Still, the
majority of our patients received anti-reflux treatment
with PPIs. Only 17% of the patients reported disappear-
ance of symptoms at the clinical follow-up. Almost half
of the patients were followed by a consultation by tele-
phone. As a previous study has displayed that symptoms
of PL treated with PPI resolve before laryngeal lesions
heal, we assumed that a telephone consultation after
2–3 months of treatment is a sufficient mode of
follow-up in the majority of cases [36]. At the telephone
consultation, if the treatment has failed to improve the
patient's symptoms, a new evaluation should be performed
and additional aetiologies of PL, e.g. allergy, voice abuse,
viral or bacterial infection, insufficient doses of PPI or
functional disease should be considered.
Patients suffering from functional oesophageal disease
are known to display typical reflux symptoms (heartburn/
regurgitations) in spite of a normal acid exposure time
and a normal oesophageal mucosa [19]. This is considered
to be due to visceral hypersensitivity, i.e. an enhanced
perception of normal physiological signals arising from
the oesophagus. Different functional disorders often over-
lap, and patients may suffer from more than one such
disorder [37]. These patients have a poorer response
to acid suppressive therapy [3,19], which also applies
to acid-suppressing therapy to patients with PL [15].
In accordance with patients affected by functional
oesophageal disease, patients diagnosed with PL might
suffer from functional pharyngeal-laryngeal disease.
Patients with FGID are known to have a comorbidity
of affective disturbances, e.g. depression and anxiety
[38], which also has been noted in patients with PL
[30]. The likelihood of a functional component is further
strengthened by the expression of serum antibodies
against gonadotropin-releasing hormone in patients both
with PL and IBS [39,40].
The men had lower scores concerning abdominal pain,
bloating and flatulence compared to the controls, whereas
women only had lower scores for abdominal pain, indicat-
ing that patients with PL suffer from more gastrointestinal
symptoms than the controls. Women have more gastro-
intestinal symptoms than men in the general population
[28,41]. On the contrary, Sadik et al. [42] found in a group
of patients with severe unexplained gastrointestinal symp-
toms, that gastrointestinal transit abnormalities were more
common in men. The VAS-IBS results in our study are in
agreement with these results [42], and suggest that the
prevalence of gastrointestinal disorders may not differ
that much between genders, when efforts are made to
objectively assess the complaints.
The present study could not prove a difference in
plasma levels of motilin between patients and controls,
but patients with reflux symptoms had lower levels of
motilin compared to those without these symptoms.
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patients with GORD, and motilin has in vitro been
shown to elicit contractions of the LOS [10,11]. Patients
with GORD, defective LOS pressure, and oesophageal
dysmotility have been found to have lower plasma
motilin levels than patients with normal peristalsis, and the
motilin levels, LOS pressure and oesophageal dysmotility
were normalised after anti-reflux surgery [43]. We have
recently shown in a group of diabetic patients that
plasma motilin concentrations vary with abnormalities
in oesophageal motility [44], and the results of the
present study raise the hypothesis that motilin might
be of importance for the LOS function and oesophageal
motility in LPR-induced PL. Basal and peak plasma levels
of motilin, 24-h combined multi-channel intra-luminal
impedance and pH testing (MII-pH) or 24-h pH monitoring
with dual probes, would be of interest to further determine
the role of motilin in patients with PL.
Siupsinskiene et al. [30] reported a significant deterior-
ation in HRQOL in PL patients. Carrau et al. [29] also
demonstrated, by using the SF-36 questionnaire, that
patients with symptoms of LPR have a significantly inferior
HRQOL than the general U.S. population.
In the present study, HRQOL was improved at the
follow-up after 43 months, compared to the initial assess-
ment. The absence of correlation between physical health
(PCS) and the physical items of the VAS-IBS confirms that
the impaired HRQOL in our patients with PL are not due
to FGID, but due to PL. The lower HRQOL of women at
the start of the study might reflect the propensity of women
to complain about their symptoms [28,41,45]. Subsequent
normalisation of their HRQOL at follow-up might be due
to adequate treatment, receiving a diagnosis and informa-
tion about the nature of their disease, or being taken care
of. Bengtsson et al. [46] have shown that being taken care
of, and information/education, improves women's quality
of life when suffering from functional diseases.
One limitation of this study is the small group of
patients studied. Also, we have not excluded the possibility
that our patients might suffer from weakly acidic, gaseous
or non-acidic reflux, as we have registered their reflux
only by pH monitoring with a single probe, and not with
combined multi-channel intra-luminal impedance and pH
testing (MII-pH) or 24-h pH double probe monitoring.
Our controls for motilin and VAS-IBS were entirely or
partly recruited from hospital staff, who may be healthier
than the average individual, and our control and study
groups might have gained from being better matched.
We have tried to compensate for this shortcoming by
statistical adjustments of the data.
Conclusion
This study indicates that patients with typical findings
and symptoms of PL to a lesser extent have LPR, andthat PL, in a subgroup of patients, may be due to func-
tional disease. Voice problems were associated with
pathological 24-h pH values. The plasma level of motilin
is affected among PL patients with typical reflux symptoms,
suggesting that this hormone is important in the pathogen-
esis of LPR. The HRQOL of the patients, especially the
women, was low initially, but improved over time. It is
highly probable that there are subgroups within PL, where
some patients may have LPR, some display dysmotility
of the oesophagus, and some patients have a functional
disease.
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